10-Q: Mountain Crest Acquisition Corp. V Reports Second Quarter 2024 Results, Announces Business Combination Agreement

Mountain Crest Acquisition Corp. V reports a net loss for the second quarter of 2024 and announces a business combination agreement with CUBEBIO Co., Ltd.

Summary

• Mountain Crest Acquisition Corp. V, a blank check company, reported a net loss of $64,591 for the three months ended June 30, 2024, and a net loss of $90,128 for the six months ended June 30, 2024.
• The company's operating expenses were $145,218 for the quarter and $228,987 for the six-month period.
• Interest income from the trust account was $75,065 for the quarter and $148,650 for the six-month period.
• The company has extended its deadline to complete a business combination to November 16, 2024, by making additional deposits into its trust account.
• A business combination agreement has been signed with CUBEBIO Co., Ltd., with a potential closing date no later than May 15, 2025.
• The company has been working to regain compliance with Nasdaq listing rules after receiving notices of non-compliance.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the company's ongoing losses, listing compliance issues, and the uncertainty surrounding its ability to complete a business combination. However, the recent business combination agreement and efforts to regain compliance provide some positive signals.

Positives

• The company has successfully regained compliance with Nasdaq's market value of listed securities requirement.
• The company has secured a business combination agreement with CUBEBIO Co., Ltd.
• The company has extended its deadline to complete a business combination, providing more time to finalize the transaction.
• The company has managed to reduce its liabilities through debt forgiveness and conversions.

Negatives

• The company has incurred net losses for both the three and six months ended June 30, 2024.
• The company has ongoing operating expenses and has not generated any operating revenue.
• The company has received notices from Nasdaq regarding non-compliance with listing rules.
• The company has a history of restating financial statements and has identified material weaknesses in internal controls.
• The company's ability to continue as a going concern is in doubt if a business combination is not completed by November 16, 2024.

Risks

• The company may not be able to complete a business combination by the extended deadline of November 16, 2024.
• The company's financial statements have been restated, indicating potential issues with internal controls.
• The company has received notices from Nasdaq regarding non-compliance with listing rules, which could lead to delisting.
• The company is dependent on its sponsor for working capital loans.
• The company's ability to continue as a going concern is in doubt if a business combination is not completed.
• The company may be subject to a 1% excise tax on share redemptions.

Future Outlook

The company intends to complete a business combination with CUBEBIO Co., Ltd. and is working to regain compliance with Nasdaq listing rules. The closing of the business combination is targeted for no later than May 15, 2025.

Management Comments

• Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution, raises substantial doubt about the Companys ability to continue as a going concern.
• Management intends to file the Form 10-K and the Form 10-Q or to submit a compliance plan to Nasdaq and take the necessary steps to regain compliance with Nasdaqs listing rules as soon as practicable.

Industry Context

The document reflects the typical challenges faced by SPACs, including the need to secure a business combination within a specific timeframe, maintain listing compliance, and manage financial resources effectively. The company's efforts to extend its deadline and secure a business combination agreement are common in the SPAC landscape.

Comparison to Industry Standards

• The financial performance of Mountain Crest Acquisition Corp. V is typical of a pre-merger SPAC, with no operating revenue and reliance on interest income from its trust account.
• The company's operating expenses are in line with other SPACs of similar size and stage.
• The company's efforts to extend its deadline and secure a business combination agreement are consistent with industry practices.
• The company's challenges with Nasdaq listing compliance are not uncommon among SPACs, particularly those that have experienced significant redemptions.
• The company's reliance on sponsor loans for working capital is a common practice in the SPAC industry.

Related Party Transactions

• The company has entered into multiple promissory note agreements with its sponsor.
• The company has an administrative support agreement with its sponsor.
• The company has converted promissory notes and vendor liabilities into common stock with its sponsor and vendors.

Stakeholder Impact

• Shareholders face the risk of potential liquidation if a business combination is not completed by the deadline.
• Shareholders may experience dilution if additional shares are issued to complete the business combination.
• Employees of the company are impacted by the uncertainty surrounding the company's future.
• Creditors of the company may be impacted by the company's financial condition and ability to repay debts.

Next Steps

• The company will work to complete the business combination with CUBEBIO Co., Ltd.
• The company will seek shareholder approval for the business combination.
• The company will continue to work to regain compliance with Nasdaq listing rules.
• The company will file its delayed Annual Report on Form 10-K for the year ended December 31, 2023 and its Quarterly Report on Form 10-Q for the quarter ended March 31, 2024.

Key Dates

Keywords

Business Combination, SPAC, CUBEBIO, Nasdaq, Financial Results, Promissory Notes, Share Redemption, Listing Compliance, Going Concern, Internal Controls